Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development.

EVT 302, a reversible and highly selective inhibitor of MAO-B in development for smoking cessation, was investigated in an ascending dose study with repeated daily dosing in a total of 84 healthy young and elderly subjects. Healthy young male subjects were treated with EVT 302 2.5, 5, 15 mg, or placebo for two weeks, and healthy elderly male and female subjects were treated with EVT 302 2.5 mg, 10 mg, or placebo for four weeks. Each treatment was received by 12 young and/or elderly subjects as appropriate. The highest dose levels exceed the expected maximum therapeutic dose planned to be used in further clinical trials. For the treatment period and part of the subsequent washout phase the subjects were confined to the clinical research unit.

The study was aimed at investigating safety/tolerability, pharmacokinetics, and pharmacodynamics (inhibition of MAO-B in platelets) during prolonged dosing with EVT 302 as compared to placebo. The study was conducted and successfully completed as planned per protocol. The results are still blinded and will become available as final evaluated data over the next two months.

The preliminary data indicate that EVT 302 was well tolerated in young and elderly subjects up to the highest dose levels tested in this study. Adverse events (AEs) classified as possibly treatment related were transient and mostly of mild intensity; only very few moderate AEs were reported. No severe or serious AEs occurred.

No clinically relevant changes in lab values of haematology or clinical chemistry were noted. In particular, there were no changes in liver function test
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... solutions for the detection of foodborne pathogens, announced plans ... of 2015 on May 7, 2015 after the close ... also host a conference call at 4:30 p.m. Eastern ... quarter financial results. During the conference call, material information ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has commenced an underwritten ... expects to grant the underwriters a 30-day option to ... shares of common stock offered in the public offering. ... can be no assurance as to whether or when ...
(Date:4/30/2015)... YORK , April 30, 2015 The following ... Board of Directors of China Cord Blood Corp (NYSE: ... the special committee of the independent directors of China Cord ... low privatization offer of $6.40 per share from Golden Meditech ... at $6.40 per share would greatly benefit Golden Med and ...
(Date:4/30/2015)... April 30, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics including high value and ... of its previously announced underwritten public offering of ... public offering price of $15.50 per share. This ... of their option to purchase up to 750,000 ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... BNVI ), a leader in the discovery and development ... and cancer, today announced,that Tom Chesterman, SVP and CFO of ... The presentation will take place on October 11, 2007 ... CA. A live audio web cast and slide presentation ...
... MEETING, Pa., Oct. 5 Genaera,Corporation (Nasdaq: ... be,presenting at two upcoming conferences, Biotech 2007 in ... in San Francisco on October,9-11, 2007. Henry ... Scientific,Officer of Genaera, is scheduled to participate in ...
... molecular structure found in seashells, University of Michigan researchers ... but lighter and transparent. , It,s made of ... shares chemistry with white glue. , Engineering professor Nicholas ... material isn,t quite stretchy enough to earn that name. ...
Cached Biology Technology:Genaera to Present at Biotech 2007 and BIO InvestorForum 2Genaera to Present at Biotech 2007 and BIO InvestorForum 3U-M research: New plastic is strong as steel, transparent 2
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... say they have assembled more completely the string of ... to imitate their owners and other sounds. The ... genome using a new technology, single molecule sequencing, and ... The team also decoded hard-to-sequence genetic material from corn ...
... known to both eat and inhabit dead whale skeletons ... unique ability to release bone-melting acid, scientists at Scripps ... recently discovered. The work is being presented at the ... Dr Sigrid Katz, a postdoctoral researcher working ...
... the average three year life span of a common rat, ... rat, a subterranean rodent native to East Africa, is impressive. ... rodent shows little decline due to aging, maintaining high activity, ... Now a collaborative of researchers in Israel and the United ...
Cached Biology News:DNA sequenced for parrot's ability to parrot 2DNA sequenced for parrot's ability to parrot 3Acid-wielding worms drill through bones at the bottom of the sea 2Naked mole rat may hold the secret to long life 2
Human ABCG2 MAb (Clone 5D3)...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... technology incorporating the sophisticated DirectDrive architecture ... new Varian NMR System is undeniably ... ,The Varian NMR System features parallel ... channel, providing pulse sequence programming power ...
Biology Products: